Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Journal of Neurology, Neurosurgery, and Psychiatry|March 5, 2015
TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic responseCarlos López-Gómez, Begoña Oliver-Martos, María-Jesús Pinto-Medel, et al.
European Journal of Hospital Pharmacy : Science and Practice|July 1, 2025
Patient experience in healthcare interventions: PROM and PREM evaluation in patients with multiple sclerosis after switching administration route of natalizumabCristina Fernández-Cuerva, Aranzazu Linares-Alarcon, María José Morales Lara, et al.
Scientific Reports|August 20, 2017
Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatmentMaría Jesús Pinto-Medel, Begoña Oliver-Martos, Patricia Urbaneja-Romero, et al.
Plos One|January 20, 2017
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNßIsaac Hurtado-Guerrero, Maria Jesús Pinto-Medel, Patricia Urbaneja, et al.
Scientific Reports|November 30, 2017
Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathwayIsaac Hurtado-Guerrero, Maria Jesus Pinto-Medel, Patricia Urbaneja, et al.
Journal of Clinical Medicine|July 30, 2020
Skin Phototype Could Be a Risk Factor for Multiple SclerosisPatricia Urbaneja, Isaac Hurtado-Guerrero, Miguel Ángel Hernández, et al.
Frontiers in Immunology|September 8, 2025
Discovery and early validation of serum protein signatures in untreated multiple sclerosis patients: identification of candidate biomarkers for diagnosis and stratificationIsabel Brichette-Mieg, Ana Alonso-Torres, Pablo Aliaga-Gaspar, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 11, 2016
Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarkerTeresa Órpez-Zafra, Jose Pavía, Isaac Hurtado-Guerrero, et al.
Journal of Clinical Medicine|April 5, 2020
Antiviral, Immunomodulatory and Antiproliferative Activities of Recombinant Soluble IFNAR2 without IFN-ß MediationIsaac Hurtado-Guerrero, Bruno Hernáez, María J Pinto-Medel, et al.
Frontiers in Immunology|January 3, 2022
Soluble Receptor Isoform of IFN-Beta (sIFNAR2) in Multiple Sclerosis Patients and Their Association With the Clinical Response to IFN-Beta TreatmentPablo Aliaga-Gaspar, Isaac Hurtado-Guerrero, Nicolas Lundahl Ciano-Petersen, et al.
Pageof 2